# üéØ AYESHA CASE STUDY - REAL-WORLD EXAMPLE

---

## **PATIENT**

**Name**: Ayesha Kiani, 38F  
**Cancer**: Ovarian (high-grade serous, presumed)  
**Germline**: CustomNext-Cancer¬Æ +RNAinsight¬Æ - NEGATIVE  
**Genes Tested**: 38 (BRCA1/2, Lynch, TP53, ATM, PALB2, etc.)  
**Result**: No pathogenic mutations, no VUS

---

## **STRATEGIC IMPLICATIONS**

1. ‚úÖ Sporadic ovarian cancer (not hereditary)
2. ‚úÖ Family members - population-level risk only
3. ‚ö†Ô∏è PARP inhibitors - less effective without germline BRCA
4. üéØ Need tumor NGS - find somatic drivers (likely TP53, possible HRD)

---

## **TREATMENT CONTEXT**

- **Line**: 3 (post-platinum progression)
- **Prior**: L1 carboplatin/paclitaxel, L2 unknown
- **CT**: Peritoneal carcinomatosis, ascites

---

## **PLATFORM ACTIONS**

1. ‚úÖ Clinical trial search (ovarian, post-platinum, no germline BRCA)
2. ‚úÖ Treatment line analysis (L3 options, cross-resistance)
3. ‚è≥ Tumor NGS integration (when available)

---

**Report**: `.cursor/ayesha/AyeshasGenetics.mdc`

---

**NEXT**: Read `11_PATIENT_REPORTS.mdc`
